Phase I/II trial of soluble-beta-1,3/1,6-glucan in children with metastatic high-risk (stage IV) neuroblastoma

Trial Profile

Phase I/II trial of soluble-beta-1,3/1,6-glucan in children with metastatic high-risk (stage IV) neuroblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2011

At a glance

  • Drugs Monoclonal antibody 3F8; Soluble beta 1,3-1,6 glucan
  • Indications Neuroblastoma
  • Focus Therapeutic Use
  • Sponsors Biotec Pharmacon
  • Most Recent Events

    • 14 Jul 2011 Status changed from active, no longer recruiting to completed, according to information in a Biotec Pharmacon media release.
    • 22 Jan 2009 New trial record.
    • 13 Jan 2009 Enrollment is now complete, according to a Biotec Pharmacon media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top